Biography

Anna-Lena Ungell received her PhD degree at the University of Gothenburg, Sweden 1985, in Comparative Pharmacology. After a PostDoctoral year at the Institute for Pharmacology and Toxicology in Würzburg, Germany, she worked in AstraZeneca R&D between 1987 to 2013.  During that period, she got experience from various areas of Biopharmaceutics and DMPK such as drug absorption and disposition in relation to various formulations, metabolism and excretion pathways, in vivo pharmacokinetics, biotransformation, reactive metabolites, prediction and assessments of Drug-Drug interactions(DDI), as well as PK and PBPK modeling, from early target to life cycle management. In AstraZeneca she had various managerial, scientific as well as DMPK project leader roles. 

Anna-Lena Ungell was employed as Senior Director and Head of Investigative ADME (iADME) in the Non-Clinical Development of New Medicines at UCB BioPharma sprl from 2013 to 2020. She led a global group of scientists having various educational levels (research associates to directors) both in Belgium and in UK, covering both in vitro, in vivo DMPK science including permeability, transporters, enzymology, biotransformation, prediction of human PK, DDI risk assessments, delivering preclinical data to projects in Neuroscience and Immunology for both new chemical small molecule entities and biologicals from early target identification to post marketing. 

Anna-Lena Ungell has had numerous (~¨100) PhD students and Master Science students throughout her career and in year 2004 she received an Associate Professorship in Pharmaceutics at Uppsala University, Sweden. Anna-Lena have ~85 publications, both original articles and book chapters and numerous posters and oral communications.